Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value

Milena Music, Marco A.J. Iafolla, Annie He Ren, Antoninus Soosaipillai, Ioannis Prassas and Eleftherios P. Diamandis
Milena Music
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marco A.J. Iafolla
2Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annie He Ren
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antoninus Soosaipillai
3Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ioannis Prassas
3Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleftherios P. Diamandis
1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
3Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.
4Department of Clinical Biochemistry, University Health Network, Toronto, Canada.
5Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eleftherios P. Diamandis
  • For correspondence: eleftherios.diamandis@sinaihealthsystem.ca
DOI: 10.1158/1535-7163.MCT-19-0132 Published October 2019
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: July 2019 to April 2021

AbstractFull-text HTMLPDF
Total1650316490

Cited By

Article Information

Volume 18, Issue 10, pp. 1844-1851

DOI 
https://doi.org/10.1158/1535-7163.MCT-19-0132
PubMed 
31363009

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received February 11, 2019
  • Revision received April 5, 2019
  • Accepted July 25, 2019
  • Published first July 30, 2019.

Article Versions

  • Previous version (July 30, 2019 - 06:56).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2019 American Association for Cancer Research.

Author Information

  1. Milena Music1,
  2. Marco A.J. Iafolla2,
  3. Annie He Ren1,
  4. Antoninus Soosaipillai3,
  5. Ioannis Prassas3, and
  6. Eleftherios P. Diamandis1,3,4,5,*
  1. 1Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
  2. 2Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
  3. 3Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada.
  4. 4Department of Clinical Biochemistry, University Health Network, Toronto, Canada.
  5. 5Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
  1. ↵*Corresponding Author:
    Eleftherios P. Diamandis, Mount Sinai Hospital, 60 Murray Street (Box 32); ACDC Laboratory Floor 6, Room L6-201-1, Toronto, ON M5T 3L9, Canada. Phone: 416-586-8443; Fax: 416-619- 5521; E-mail: eleftherios.diamandis{at}sinaihealthsystem.ca
  1. M. Music and M.A.J. Iafolla contributed equally to this article.

View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 18 (10)
October 2019
Volume 18, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value
Milena Music, Marco A.J. Iafolla, Annie He Ren, Antoninus Soosaipillai, Ioannis Prassas and Eleftherios P. Diamandis
Mol Cancer Ther October 1 2019 (18) (10) 1844-1851; DOI: 10.1158/1535-7163.MCT-19-0132

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value
Milena Music, Marco A.J. Iafolla, Annie He Ren, Antoninus Soosaipillai, Ioannis Prassas and Eleftherios P. Diamandis
Mol Cancer Ther October 1 2019 (18) (10) 1844-1851; DOI: 10.1158/1535-7163.MCT-19-0132
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Predictive ERBB Mutations
  • BRCA1/MAD2L1 Expression Predicts Response to Vinorelbine
  • HLA Polymorphisms Predict TFR in CML
Show more Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement